GOSSAMER BIO, INC. Comprehensive Income
GOSSAMER BIO, INC. (GOSS) reported Comprehensive Income of $17.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- GOSSAMER BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $17.19M.
- GOSSAMER BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$45.54M.
- GOSSAMER BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$47.28M.
- GOSSAMER BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$48.24M.
- GOSSAMER BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$176.71M.
- GOSSAMER BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$54.99M.
- GOSSAMER BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$179.59M.
- GOSSAMER BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$230.00M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.19M 10-Q · filed 2026-08-13 | -$28.35M 10-Q · filed 2026-08-13 | -$75.63M derived: sum of 3 quarters · filed 2026-08-13 | -$123.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$45.54M 10-Q · filed 2026-05-15 | -$92.82M derived: sum of 2 quarters · filed 2026-05-15 | -$141.06M derived: sum of 3 quarters · filed 2026-05-15 | -$183.60M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$47.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$95.52M derived: sum of 2 quarters · filed 2026-03-17 | -$138.06M derived: sum of 3 quarters · filed 2026-08-13 | -$176.71M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$48.24M 10-Q · filed 2025-11-05 | -$90.78M derived: sum of 2 quarters · filed 2026-08-13 | -$129.43M 10-Q · filed 2025-11-05 | -$159.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$42.54M 10-Q · filed 2026-08-13 | -$81.19M 10-Q · filed 2026-08-13 | -$110.80M derived: sum of 3 quarters · filed 2026-08-13 | -$143.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$38.65M 10-Q · filed 2026-05-15 | -$68.26M derived: sum of 2 quarters · filed 2026-05-15 | -$100.78M derived: sum of 3 quarters · filed 2026-05-15 | -$51.43M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$29.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$62.13M derived: sum of 2 quarters · filed 2026-03-17 | -$12.78M derived: sum of 3 quarters · filed 2026-03-17 | -$54.99M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$32.52M 10-Q · filed 2025-11-05 | $16.83M derived: sum of 2 quarters · filed 2025-11-05 | -$25.38M 10-Q · filed 2025-11-05 | -$73.26M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $49.34M 10-Q · filed 2025-08-05 | $7.14M 10-Q · filed 2025-08-05 | -$40.74M derived: sum of 3 quarters · filed 2026-03-17 | -$80.89M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$42.21M 10-Q · filed 2025-05-15 | -$90.09M derived: sum of 2 quarters · filed 2026-03-17 | -$130.23M derived: sum of 3 quarters · filed 2026-03-17 | -$172.77M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$47.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$88.03M derived: sum of 2 quarters · filed 2026-03-17 | -$130.57M derived: sum of 3 quarters · filed 2026-03-17 | -$179.59M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$40.15M 10-Q · filed 2024-11-07 | -$82.69M derived: sum of 2 quarters · filed 2024-11-07 | -$131.71M 10-Q · filed 2024-11-07 | -$187.47M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$42.54M 10-Q · filed 2024-08-12 | -$91.57M 10-Q · filed 2024-08-12 | -$147.32M derived: sum of 3 quarters · filed 2025-03-13 | -$206.75M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$49.03M 10-Q · filed 2024-05-07 | -$104.78M derived: sum of 2 quarters · filed 2025-03-13 | -$164.21M derived: sum of 3 quarters · filed 2025-03-13 | -$220.85M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$55.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$115.19M derived: sum of 2 quarters · filed 2025-03-13 | -$171.83M derived: sum of 3 quarters · filed 2025-03-13 | -$230.00M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$59.43M 10-Q · filed 2023-11-09 | -$116.07M derived: sum of 2 quarters · filed 2023-11-09 | -$174.24M 10-Q · filed 2023-11-09 | -$230.62M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$56.64M 10-Q · filed 2023-08-08 | -$114.81M 10-Q · filed 2023-08-08 | -$171.19M derived: sum of 3 quarters · filed 2024-03-05 | -$231.57M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | -$58.17M 10-Q · filed 2023-05-09 | -$114.55M derived: sum of 2 quarters · filed 2024-03-05 | -$174.93M derived: sum of 3 quarters · filed 2024-03-05 | -$234.65M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | -$56.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$116.76M derived: sum of 2 quarters · filed 2024-03-05 | -$176.48M derived: sum of 3 quarters · filed 2024-03-05 | -$234.56M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$60.38M 10-Q · filed 2022-11-03 | -$120.10M derived: sum of 2 quarters · filed 2022-11-03 | -$178.18M 10-Q · filed 2022-11-03 | -$242.53M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | -$59.72M 10-Q · filed 2022-08-09 | -$117.80M 10-Q · filed 2022-08-09 | -$182.15M derived: sum of 3 quarters · filed 2023-03-17 | -$240.18M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | -$58.08M 10-Q · filed 2022-05-10 | -$122.43M derived: sum of 2 quarters · filed 2023-03-17 | -$180.47M derived: sum of 3 quarters · filed 2023-03-17 | -$246.26M derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | -$64.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$122.38M derived: sum of 2 quarters · filed 2023-03-17 | -$188.18M derived: sum of 3 quarters · filed 2023-03-17 | -$243.02M 10-K · filed 2023-03-17 |
| 2020-09-30 | -$58.04M 10-Q · filed 2021-11-08 | -$123.83M derived: sum of 2 quarters · filed 2021-11-08 | -$178.67M 10-Q · filed 2021-11-08 | -$233.44M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | -$65.80M 10-Q · filed 2021-08-09 | -$120.64M 10-Q · filed 2021-08-09 | -$175.40M derived: sum of 3 quarters · filed 2022-03-03 | -$224.07M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | -$54.84M 10-Q · filed 2021-05-06 | -$109.61M derived: sum of 2 quarters · filed 2022-03-03 | -$158.27M derived: sum of 3 quarters · filed 2022-03-03 | -$202.35M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | -$54.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$103.44M derived: sum of 2 quarters · filed 2022-03-03 | -$147.52M derived: sum of 3 quarters · filed 2022-03-03 | -$179.99M 10-K · filed 2022-03-03 |
| 2019-09-30 | -$48.67M 10-Q · filed 2020-11-10 | -$92.75M derived: sum of 2 quarters · filed 2020-11-10 | -$125.22M 10-Q · filed 2020-11-10 | -$164.31M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$44.08M 10-Q · filed 2020-08-11 | -$76.55M 10-Q · filed 2020-08-11 | -$115.64M derived: sum of 3 quarters · filed 2021-02-26 | -$164.81M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$32.47M 10-Q · filed 2020-05-12 | -$71.56M derived: sum of 2 quarters · filed 2021-02-26 | -$120.73M derived: sum of 3 quarters · filed 2021-02-26 | -$153.46M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$39.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$88.26M derived: sum of 2 quarters · filed 2021-02-26 | -$120.99M derived: sum of 3 quarters · filed 2021-02-26 | -$147.03M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$49.17M 10-Q · filed 2019-11-12 | -$81.90M derived: sum of 2 quarters · filed 2019-11-12 | -$107.94M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$32.73M 10-Q · filed 2019-08-08 | -$58.77M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$26.04M 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | -$6.77M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |